Development of Succinate-based analogues and formulations against SARS-CoV-2 and influenza viruses-induced respiratory infections – SuccesS
The emergence of pandemic respiratory viruses is a major concern. Those viruses include coronaviruses such as SARS-CoV-2 and influenza A viruses (IAV). There are currently no efficient drugs against coronaviruses and the efficacy of anti-IAV drugs is disputed. Vaccination should constitute the most preventive strategy. However, the intrinsic antigenic drift of IAV impairs vaccine protection. Besides, previous coronaviruses crises showed that poorly neutralizing antibodies developed after vaccination may enhance subsequent infection. Current vaccine hesitancy also remains a barrier to full population inoculation against SARS-CoV-2. Our ANR project is thus aimed to develop an innovative metabolic therapy against those two viruses, delivered via the pulmonary route, based on (i) recent evidence that metabolites are key effectors of the host antimicrobial response and (ii) our preliminary data which identified two metabolites with anti-IAV and anti-SARS-CoV-2 antiviral activity.
Monsieur Mustapha SI-TAHAR (Centre d'Etude des Pathologies Respiratoires)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
CEPR Centre d'Etude des Pathologies Respiratoires
UPSaclay-BioCIS Université Paris Saclay-BioCIS UMR 8076
IGPS Institut Galien Paris Saclay
Help of the ANR 666,747 euros
Beginning and duration of the scientific project: January 2022 - 42 Months